Please login to the form below

Not currently logged in
Email:
Password:

Merck & Co appoints new financial head

Baxter’s Robert Davis takes over from Peter Kellogg
Robert Davis Merck

Merck & Co's long-time chief financial officer Peter Kellogg is to step down within the next two months and will be replaced by Baxter's Robert Davis.

Kellogg had been in the position since joining Merck in 2007 and played a key role in the pharma company's merger with Schering-Plough.

To help with the transition, Kellogg will work closely with Davis (pictured) when he joins on April 23, staying with Merck until May 16.

Davis, who currently serves as VP and president of Baxter's medical products business – a role he has held since 2010, also has great industry experience.

He first joined Baxter in 2004 as chief financial officer of the company's renal business and prior to this spent 14 years at Lilly.

Commenting on the departure of Kellogg, Merck's CEO Kenneth Frazier said: "Peter has been an important member of the Merck leadership team and instrumental in helping to guide Merck during a period of significant change at our company and in our industry.”

31st March 2014

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Apex.co.uk Conferences, Events and Exhibition Stands

Apex.co.uk is one of the UK’s leading event and exhibition agencies, specialising in healthcare. We understand your communication goals, whether...

Latest intelligence

Genomics integration: can the NHS rise to the challenge?
Experts gather to discuss the UK’s genomic landscape...
London
“Brexit has been a catalyst for UK clinical research... it’s turbocharged change”
The UK clinical trials environment has been transformed in recent years – but can it really buck Brexit’s risks and uncertainties?...
The Future of Pharma sales: fast forward to 2029
Change is inevitable, and necessary, for growth in business....

Infographics